ReviewRenal failure2025
Clinical and pathological features of patients with recurrent anti-glomerular basement membrane disease.
Review in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-glomerular basement membrane disease (anti-GBM disease) is a rare autoimmune disease, traditionally considered a monophasic autoimmune disorder, but more and more cases of recurrence have been reported. Through a review of the published literature and analysis of recurrent cases from our institution, we identified key predisposing factors including smoking (21.7%), hydrocarbon exposure (7.2%), prodromal infections (12.0%), and comorbid autoimmune conditions (12.0%). Notably, 43.5% (20/46) of recurrences occurred without identifiable triggers. There are not a few antibody-negative recurrences, challenging the reliability of serological monitoring alone for disease activity, and such recurrences may have an underlying unrecognized pathogenesis. Clinical presentations at recurrence varied: 38.6% of the patients had both lung and kidney involvement, 33.3% had lung involvement only, and 28.1% had kidney involvement only. Patients with concurrent systemic autoimmune diseases exhibited universally poor renal outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.